A global phase 3 efficacy and safety trial of KSHB002
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Abatacept (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; Registrational; Therapeutic Use
- 03 Feb 2025 New trial record